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α-TocopherolTaking into account that pro-inﬂammatory cytokines and oxidative and nitrosative stress are implicated in
the pathogenesis of depression and that α-tocopherol has antidepressant, anti-inﬂammatory and antioxidant
properties, this study investigated the ability of α-tocopherol to abolish the depressive-like behavior induced
by i.c.v. administration of TNF-α in the mouse TST. Additionally, we investigated the occurrence of changes in
the levels of Bcl2 and Bax and phosphorylation of GSK-3β (Ser9) in the hippocampus of mice. The administra-
tion of TNF-α (0.001 fg/site, i.c.v.) increased the immobility time in the TST, which was prevented by the
administration of α-tocopherol at the doses of 10, 30 and 100 mg/kg (p.o.). Subeffective doses of α-tocopherol
(10 mg/kg, p.o.) and/or the antidepressants ﬂuoxetine (5 mg/kg, p.o.), imipramine (0.1 mg/kg, p.o.) and
bupropion (1 mg/kg, p.o.), the NMDA receptor antagonist MK-801 (0.001 mg/kg, p.o.) or the neuronal nitric
oxide synthase inhibitor 7-nitroindazole (25 mg/kg, i.p.) prevented the depressive-like effect induced by
TNF-α. None of the treatments altered the locomotor activity of mice. Treatment with TNF-α and/or
α-tocopherol did not alter the levels of Bax and Bcl2 or the phosphorylation of GSK-3β in the hippocampus of
mice. Together, our results show a synergistic antidepressant-like effect of α-tocopherol with antidepressants
against the depressive-like behavior induced by an inﬂammatory insult, suggesting that this vitamin may be
useful to optimize conventional pharmacotherapy of depression, including depressive states associated with
inﬂammatory conditions.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Depression is a neuropsychiatric disorder that has a high rate of
comorbidity and mortality, beyond providing high social and personal
costs (Simon, 2003). Among the various factors involved in the patho-
physiology of depression, it is known that changes in inﬂammatory
pathways are correlated with this mood disorder (Dantzer et al.,
2008). The relationship between depression and inﬂammation was
established based on numerous studies and meta-analysis showing
that depressive patients have increased inﬂammatory markers such as
interleukin (IL)-6 and tumor necrosis factor-α (TNF-α) (Dowlati et al.,
2010; Howren et al., 2009). Besides, the presence of some inﬂammatory
diseases, such as inﬂammatory bowel disease, multiple sclerosis,
psoriasis, rheumatoid arthritis, and neuro-inﬂammatory disorders, is
believed to increase the risk for the development of depression (Graffd swimming test; GSK-3, glyco-
.v., intracerebroventricular; i.p.,
c oxide; nNOS, neuronal nitric
T, tail suspension test; TNF-α,
: +55 48 3721 9672.
s@ufsc.br (A.L.S. Rodrigues).
rights reserved.et al., 2009). Corroborating the inﬂammatory hypothesis of depression,
it was demonstrated that patients with cancer or chronic hepatitis C,
who are treated with inﬂammatory cytokines, have a higher risk of
depression (Bonaccorso et al., 2001; Capuron et al., 2000). Similarly, it
has been shown that the administration of proinﬂammatory cytokines,
such as interferon (IFN)-α and TNF-α induces a depressive-like behav-
ior in mice (Kaster et al., 2012; Ping et al., 2012).
It is known that an excessive activation of inﬂammatory pathways in
the brain can lead tomany consequenceswhich are also seen in depres-
sion, such as increased oxidative and nitrosative stress, decreased
neurotrophic factors, glutamatergic excitotoxicity and loss of glial
elements (Maes, 2008; McNally et al., 2008). Moreover, an excess of
inﬂammatory cytokines in the central nervous system (CNS) decreases
serotonin production, enhancing the kynurenine pathway. As a result of
overactivation of this pathway, there is an increased level ofmetabolites
that include quinolinic acid, an N-methyl-D-aspartate (NMDA) receptor
agonist (subtype of ionotropic glutamate receptor), whichmay contrib-
ute to elevate the risk of glutamatergic excitotoxicity (McNally et al.,
2008; Myint et al., 2012).
Inﬂammation also can inﬂuence neuronal function because inﬂamma-
tory cytokines such as TNF-α and IFN-γ may alter metabolic processes,
oxidative and nitrosative stress, excitotoxicity and apoptosis (Hayley
et al., 2005). TNF-α, a cytokine used in this study, has been shown to
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degeneration (Patel et al., 2006; Viviani et al., 2004).
It is important to be mentioned that decreased hippocampal
volume, commonly observed in depressive patients, is closely related
to reduced neurogenesis and/or increased neuronal/glial death, a
scenario also observed in the presence of high levels of inﬂammatory
cytokines (MacQueen et al., 2003; Malykhin et al., 2010). Various pro-
teins are involved in the cell death process, among which stands out
the Bcl2 family. This set of proteins integrates death and/or cell survival
signals generated within or outside the cell, regulating cell death
induced by apoptosis (Borner, 2003). Bcl2 family is divided into two
classes: pro-apoptotic members such as Bax and Bak and antiapoptotic
members such as Bcl2 and Bcl-xL (Antonsson, 2001; Borner, 2003).
Another protein that has been shown to be involved in the modulation
of apoptosis is the enzyme glycogen synthase kinase-3β (GSK-3β), that
is inhibited by phosphorylation at the serine 9 residue (Beaulieu et al.,
2009). Activation of GSK-3β has been shown to promote apoptosis in
a wide variety of conditions, including neurodegenerative diseases
and depression (Jope and Johnson, 2004; Maes et al., 2012). Besides
its involvement in apoptosis, GSK-3β is also important in regulating
the inﬂammatory response (Cortes-Vieyra et al., 2012). Additionally,
some studies have shown an association between GSK-3β and animal
models of depression, and inhibition of this protein is associated, at
least partly, with the therapeutic action of antidepressant agents
(Beaulieu et al., 2008; Budni et al., 2011).
The oxidative and nitrosative stress has also been associated with
the pathophysiology of depression. It may result in lipid peroxidation,
protein and DNA oxidation, membrane disruption, cell permeation,
apoptosis, modifying the cellular signaling, differentiation, and prolif-
eration, increasing the inﬂammation and producing deleterious cellu-
lar effects, contributing to the development or severity of depression
(Behr et al., 2012; Maes et al., 2011; Ng et al., 2008; Sarandol et al.,
2007). Furthermore, both inﬂammation and oxidative and nitrosative
stress may contribute to neurodegeneration processes, increasing the
neuronal apoptosis and reducing the neurogenesis and the production
of neurotrophic factors, events that together may contribute to the
phenotype of depression (Kubera et al., 2011; Leonard and Maes,
2012;Moylan et al., 2013). Interestingly, some antidepressants have an-
tioxidant and anti-inﬂammatory effects (Abdel-Salam et al., 2004; Behr
et al., 2012; Zaﬁr et al., 2009) and some antioxidants (e.g. N-acetyl-L-
cysteine, green tea polyphenols, ascorbic acid) have been reported to
exert antidepressant-like effects (Ferreira et al., 2008; Moretti et al.,
2011, 2012; Zhu et al., 2012).
Besides the involvement of inﬂammation and oxidative and
nitrosative stress, it is reported that the hyperactivity of glutamatergic
system, particularly through NMDA receptors, is also involved in the
pathophysiology of depression (Skolnick, 1999; Zarate et al., 2010).
This hypothesis is reinforced by preclinical and clinical studies showing
that NMDA receptor antagonists have antidepressant activity (Garcia
et al., 2008; Sanacora et al., 2012). Furthermore, NMDA receptor antag-
onists such as MK-801 and ketamine were also reported to possess
anti-inﬂammatory action, a property that may contribute to their anti-
depressant effect (Esposito et al., 2011;Wu et al., 2012). A consequence
of the activation of NMDA receptors is the stimulation of neuronal nitric
oxide synthase (nNOS), which converts L-arginine to nitric oxide (NO)
and L-citrulline (Calabrese et al., 2007; Steinert et al., 2010). NO has
been considered a neurotransmitter substance, but it is also involved
in CNS disorders, including depression, which has been associated
with increased levels of NO in the brain (Dhir and Kulkarni, 2011).
Although the current treatment for depression is usually safe, it is
still not ideal, since it has some limitations, in addition to presenting
several side effects (Nemeroff and Owens, 2002). Given the limited
effectiveness of current treatment options, our group has studied
the antidepressant-like effect of some nutrients (Budni et al.,
2011; Moretti et al., 2013), aiming at improving the treatment of
depression.Vitamin E is a fat soluble vitamin that includes eight different
chemical analogs present in foods: alpha (α), beta (β), gamma (γ)
and delta (δ)-tocopherol and α-, β-, γ- and δ-tocotrienol, and of
these, α-tocopherol is the most abundant in foods (Traber, 2007).
α-Tocopherol has several functions for humans, including antioxidant,
anti-inﬂammatory, anticancer and antiatherogenic activities, direct
effects on enzymatic activity and regulation in the transcription of
some genes (Schneider, 2005; Tucker and Townsend, 2005). Further-
more, besides α-tocopherol has been shown to exhibit antidepressant
properties in preclinical studies (Lobato et al., 2010), clinical studies
demonstrated that patients with depression had lower serum (Maes
et al., 2000) or plasma (Owen et al., 2005) levels of vitamin E.
Considering this background regarding the involvement of inﬂam-
mation and oxidative and nitrosative stress in the pathophysiology of
depression and taking into account the potential anti-inﬂammatory
and antioxidant of α-tocopherol, in the present study we evaluated
the antidepressant-like effect of α-tocopherol in an animal model of
depressive-like behavior induced by TNF-α. Moreover we evaluated
the potential synergistic effect of the combined administration of
subeffective doses of α-tocopherol and conventional antidepressants,
as well as the combined effect of subeffective doses of α-tocopherol
and the NMDA receptor antagonist MK-801 or the neuronal nitric
oxide synthase inhibitor 7-nitroindazole in the model of depressive-
like behavior induced by TNF-α.
2. Materials and methods
2.1. Animals
The experiments were conducted using female Swiss mice (45–
55 days old, weighing 30–45 g), maintained at 20–22 °C with free
access to water and food, under a 12:12 h light/dark cycle (lights on
at 7:00 a.m.). All behavioral tests were carried out between 9:00 a.m.
and 04:00 p.m. All experiments were performed on separate groups
of animals and each animalwas used only once in each test. The animals
were used according to the NIH Guide for the Care and Use of Laborato-
ry Animals and the experiments were performed after approval of the
protocol by the Ethics Committee of the Institution. All efforts were
made to minimize animal suffering and to reduce the number of
animals used in the experiments.
2.2. Drugs and treatment
The following drugs were used: DL-all-rac-α-tocopherol (10, 30 and
100 mg/kg), ﬂuoxetine (5 mg/kg; selective serotonin reuptake inhibi-
tor), imipramine (0.1 mg/kg; tricyclic antidepressant), bupropion
(1 mg/kg; dopamine and noradrenaline reuptake inhibitor), MK-801
(0.001 mg/kg; NMDA receptor antagonist), 7-nitroindazole (25 mg/kg;
nNOS inhibitor), and TNF-α from mouse (0.001 fg/site). All these
drugs were obtained from Sigma Chemical Co., St. Louis, USA, except
bupropion that was obtained from Libbs Farmaceutica Ltda. (Brazil).
α-Tocopherol was dissolved in mineral oil with 10% of ethanol and ad-
ministered orally (p.o.); ﬂuoxetine, imipramine, bupropion and
MK-801 were dissolved in distilled water and administered by p.o.
route; 7-nitroindazole was dissolved in saline with 5% Tween 80 and
administered by intraperitoneal (i.p.) route; and TNF-α was dissolved
in saline (0.9% NaCl) and administered by intracerebroventricular
(i.c.v.) route. The drugs were freshly prepared before administration
and administered in a volume of 10 ml/kg body weight (p.o. and i.p.
route) or 5 μl/site (i.c.v.). Control animals received the appropriate
vehicles.
I.c.v. administration was performed as described by Kaster et al.
(2012). For injection, 26G needle was attached to a polypropylene
cannula coupled to a 50 μl-Hamilton microsyringe. The mice were
lightly anesthetized with ether (only for the loss of the postural
reﬂex) and the administration was performed by inserting the needle
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brain of the mice. The injection was given over 30 s, and the needle
remained in place for another 30 s in order to avoid the reﬂux of
the substances injected. The injection site was 1 mm to the right or
left from the midpoint on a line drawn through to the anterior base
of the ears. The injections were performed by an experienced person,
and after dissection of the brain of the animal, the success of the in-
jection was examined, macroscopically, discarding animals whose in-
jection has been held in place inappropriate or has caused cerebral
hemorrhage (b5%).
To investigate the effect of α-tocopherol in an animal model of
depressive-like behavior induced by TNF-α, mice were treated (p.o.)
with vehicle or three doses of α-tocopherol (10, 30 or 100 mg/kg).
After 30 min, they received an injection (i.c.v.) of TNF-α (0.001 fg/site,
i.c.v.) or vehicle (saline). After another 30 min, the animals were
subjected to behavioral tests. The dose of TNF-α and α-tocopherol was
chosen based on previous studies from our group (Kaster et al., 2012;
Lobato et al., 2010).
In another set of experiments, mice received (p.o.) vehicle or
subeffective doses of ﬂuoxetine, imipramine, bupropion or MK-801.
Immediately after, they were treated with a subeffective dose of
α-tocopherol (10 mg/kg, p.o.) or vehicle. After 30 min, they received
an i.c.v. injection of TNF-α or vehicle, 30 min before being tested in
the tail suspension test (TST) or open-ﬁeld paradigm.
To investigate a possible synergistic effect between α-tocopherol
and 7-nitroindazole, mice received (p.o.) vehicle or a subeffective
dose of α-tocopherol. After 30 min, they received (i.p.) a subeffective
dose of 7-nitroindazole or vehicle and immediately after, an injection
(i.c.v.) of TNF-α or vehicle. The behavioral tests were performed
30 min after the end of the last treatment.
The doses of antidepressants, MK-801 and 7-nitroindazole used
were chosen based on experiments previously performed in our labora-
tory (Binfaré et al., 2009; Brocardo et al., 2008).
2.3. Behavioral tests
2.3.1. Tail suspension test (TST)
The total duration of immobility induced by tail suspension was
measured according to the method described by Steru et al. (1985).
Mice both acoustically and visually isolated were suspended 50 cm
above the ﬂoor by adhesive tape placed approximately 1 cm from
the tip of the tail. Mice were considered immobile only when they
hung passively and completely motionless. The immobility time was
recorded during a 6-min period by an experienced observer blind to
the animal condition.
2.3.2. Open-ﬁeld test
In order to rule out the possibility that the alteration in the immobil-
ity time in the TSTwas due to interference of the locomotor activity, the
animals were subjected to an open-ﬁeld test for 6 min, as described by
Moretti et al. (2013). This test was carried out in awooden boxmeasur-
ing 40 × 60 × 50 cm, with the ﬂoor of the arena divided into 12 equal
squares. The number of squares crossed with all four paws (crossings)
wasmanually counted andwas the parameter used to evaluate locomo-
tor activity. The apparatus was cleaned with a solution of 10% ethanol
between tests in order to hide animal clues.
2.4. Biochemical analysis
An independent group of mice was used for biochemical analysis.
Animals received (p.o.) vehicle, an active dose of bupropion (10 mg/kg)
or two doses ofα-tocopherol: 10 mg/kg (subeffective dose) or 30 mg/kg
(active dose). After 30 min, the animals received an injection (i.c.v.) of
TNF-α or vehicle (saline). After another 30 min, the animalswere decap-
itated for biochemical analysis.2.4.1. Tissue preparation
After decapitation, the brain of each animal was removed and the
hippocampi were quickly dissected (4 °C), placed in liquid nitrogen
and stored at−80 °C until use. The sampleswere prepared as described
previously (Oliveira et al., 2008). Brieﬂy, samplesweremechanically ho-
mogenized in 400 μl of TRIS 50 mM pH 7.0, EDTA 1 mM, NaF 100 mM,
PMSF 0.1 mM, Na3VO4 2 mM, Triton X-100 1%, glycerol 10%, and
Sigma Protease Inhibitor Cocktail (P2714) and then incubated for
10 min in ice. Lysates were centrifuged (10.000 ×g for 10 min, at 4 °C)
to eliminate cellular debris. The supernatants were diluted 1/1 (v/v) in
TRIS 100 mM pH 6.8, EDTA 4 mM, and SDS 8% and boiled for 5 min.
Thereafter, sample dilution (40% glycerol, 100 mM TRIS, bromophenol
blue, pH 6.8) in the ratio 25:100 (v/v) andβmercaptoethanol (ﬁnal con-
centration 8%)were added on the samples. Protein content was estimat-
ed at 620 nm wavelength and the concentration calculated using a
standard curvewith bovine serumalbumin as standard (Peterson, 1977).
2.4.2. Western blotting
The same amount of protein (60 μg per lane) for each sample was
electrophoresed in SDS-PAGEminigels (10% acrylamide for the analysis
of GSK-3β and 12% acrylamide for the analysis of Bax, Bcl2, and β-actin)
and transferred to nitrocellulose membranes using a tank transfer
system at 100 V and 270 mA for 1 h (Mini-PROTEAN Tetra Cell Electro-
phoresis System, Bio-Rad, Hercules, CA) (Cordova et al., 2004). To verify
transfer efﬁciency process, gels were stained with Coomassie blue and
membranes with Ponceau S.
The membranes were blocked with 5% skim milk in TBS (TRIS
10 mM, NaCl 150 mM, pH 7.5). GSK-3β total and phosphorylated
(Ser9) forms, Bax and Bcl2 immunocontents were detected using spe-
ciﬁc antibodies incubated overnight diluted in TBS-T (10 mM TRIS,
150 mMNaCl, 0.1% Tween-20, pH 7.5) containing 2.5% BSA in the dilu-
tions 1:1.000. Next, the membranes were incubated with anti-rabbit
peroxidase-linked secondary antibody (1:5.000) for 1 h and the reac-
tions developed by chemiluminescence (LumiGLOH, Cell Signaling,
Beverly, MA, USA). All blocking and incubation steps were followed by
threewashes (5 min) of themembraneswith TBS-T. The optical density
(O.D.) of the bands was quantiﬁed using the Scion Image™ (Frederick,
MD, USA). The phosphorylation levels of GSK-3β were determined as
a ratio of the O.D. of the phosphorylated band over the O.D. of the
total band. The immunocontent of Bcl2 and Bax was determined as a
ratio of the O.D. of the Bcl2 or Bax band over the O.D. of the β-actin
band. Data were expressed as percentage of the control (considered as
100%).
The antibodies anti-phospho-GSK-3β (Ser9), anti-GSK-3β, anti-Bax,
anti-Bcl2 and anti-β-actin detected a single band of approximately
46 kDa, 46 kDa, 20 kDa, 28 kDa and 45 kDa, respectively.
2.5. Statistical analysis
All data are presented as mean + SEM. Differences among exper-
imental groups were determined by two-way or three-way ANOVA
followed by Duncan's multiple range post hoc test, when appropriate.
A value of P b 0.05 was considered to be signiﬁcant.
3. Results
3.1. Behavioral observations
3.1.1. Investigation of the acute effect of α-tocopherol in TNF-α-treated
mice
Fig. 1A shows that systemic acute administration (p.o.) of
α-tocopherol at doses of 30 and 100 mg/kg, produced a reduction
in immobility time in the TST as compared to control mice, while
the dose of 10 mg/kg was ineffective. Furthermore, the administration
of TNF-α (i.c.v.) increased the immobility time in the TST, an effect
prevented by the acute administration of the α-tocopherol at doses of
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Fig. 1. Effect of treatment with α-tocopherol (T) at different doses (ranging from 10 to
100 mg/kg, p.o.) associatedwith administration of TFN-α (0.001 fg/site; i.c.v.) or vehicle on
the immobility time in the TST (panel A) and on number of crossings in the open-ﬁeld test
(panel B). Bars represent means + SEM (n = 8). *P b 0.05 compared with the control
group (vehicle). **P b 0.01 compared with control group (vehicle). ##P b 0.01 compared
with the group treatedwith TNF-α. (Two-way ANOVA followed by Duncan's post hoc test).
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P N 0.05], α-tocopherol treatment [F(3,56) = 22.18, P b 0.01],
TNF-α × α-tocopherol [F(3,56) = 9.57, P b 0.01]).
None of the treatments caused changes in locomotor activity in
the open-ﬁeld test (Fig. 1B) (TNF-α treatment [F(1,56) = 0.50,
P N 0.05], α-tocopherol treatment [F(3,56) = 0.88, P N 0.05], TNF-α ×
α-tocopherol treatment interaction [F(3,56) = 1.48, P N 0.05]).
3.1.2. Effects of the combined administration of α-tocopherol and
antidepressants in TNF-α-treated mice
Fig. 2 shows that acute administration of a subeffective dose of
α-tocopherol (10 mg/kg, p.o.) in combination with subeffective doses
of ﬂuoxetine (panel A), imipramine (panel C) or bupropion (panel E)
decreased the immobility time in the TST, whereas the administration
of drugs alone did not change the immobility time. Fig. 2 also shows
that the administration of TNF-α produced an increased immobility
time in the TST, which was prevented by the acute administration of
α-tocopherol and antidepressants alone or in combination. In addition,
in animals that received TNF-α, the combined treatment with
α-tocopherol and imipramine (panel C) or bupropion (panel E) pro-
duced a synergistic antidepressant-like effect, since the immobility
time in the TST was statistically lower as compared to the one obtained
in the groups that received α-tocopherol, imipramine or bupropion
alone (ﬂuoxetine: TNF-α treatment [F(1,54) = 0.50, P N 0.05],
α-tocopherol treatment [F(1,54) = 28.60, P b 0.01], ﬂuoxetine
treatment [F(1,54) = 46.32, P b 0.01], TNF-α × α-tocopherol treatment
interaction [F(1,54) = 10.45, P b 0.01], TNF-α × ﬂuoxetine treatment
interaction [F(1,54) = 2.12, P N 0.05], α-tocopherol × ﬂuoxetine treat-
ment interaction [F(1,54) = 1.29, P N 0.05], TNF-α × α-tocopherol ×
ﬂuoxetine treatment interaction [F(1,54) = 15.56, P b 0.01]; imipramine:
TNF-α treatment [F(1,56) = 0.03, P N 0.05], α-tocopherol treatment[F(1,56) = 19.65, P b 0.01], imipramine treatment [F(1,56) = 48.26,
P b 0.01], TNF-α × α-tocopherol treatment interaction [F(1,56) =
17.78, P b 0.01], TNF-α × imipramine treatment interaction [F(1,56) =
5.66, P b 0.05], α-tocopherol × imipramine treatment interaction
[F(1,56) = 0.162, P N 0.05], TNF-α × α-tocopherol × imipramine
treatment interaction [F(1,56) = 4.98, P b 0.05]; bupropion: TNF-α
treatment [F(1,56) = 0.38, P N 0.05], α-tocopherol treatment
[F(1,56) = 30.54, P b 0.01], bupropion treatment [F(1,56) = 56.58,
P b 0.01], TNF-α × α-tocopherol treatment interaction [F(1,56) =
11.52, P b 0.01], TNF-α × bupropion treatment interaction [F(1,56) =
1.34, P b 0.05], α-tocopherol × bupropion treatment interaction
[F(1,56) = 0.01, P N 0.05], TNF-α × α-tocopherol × bupropion treat-
ment interaction [F(1,56) = 18.10, P b 0.01]).
None of the treatments caused changes in locomotor activity in the
open-ﬁeld test (Fig. 2B, D, F) (ﬂuoxetine: TNF-α treatment [F(1,56) =
0.02, P = 0 N 0.05], α-tocopherol treatment [F(1,56) = 0.80, P N 0.05],
ﬂuoxetine treatment [F(1,56) = 5.63, P b 0.05], TNF-α × α-tocopherol
treatment interaction [F(1,56) = 0.06, P N 0.05], TNF-α × ﬂuoxetine
treatment interaction [F(1,56) = 0.41, P N 0.05], α-tocopherol ×
ﬂuoxetine treatment interaction [F(1,56) = 0.53, P N 0.05], TNF-α ×
α-tocopherol × ﬂuoxetine treatment interaction [F(1,56) = 0.03,
P N 0.05]; imipramine: TNF-α treatment [F(1,54) = 0.67, P N 0.05],
α-tocopherol treatment [F(1,54) = 3.84, P N 0.05], imipramine treat-
ment [F(1,54) = 0.98, P N 0.05], TNF-α × α-tocopherol treatment
interaction [F(1,54) = 0.30, P N 0.05], TNF-α × imipramine treatment
interaction [F(1,54) = 0.06, P N 0.05],α-tocopherol × imipramine treat-
ment interaction [F(1,54) = 1.70, P N 0.05], TNF-α ×α-tocopherol ×
imipramine treatment interaction [F(1,54) = 0.20, P N 0.05]; bupropion:
TNF-α treatment [F(1,56) = 0.02, P N 0.05], α-tocopherol treatment
[F(1,56) = 1.03, P N 0.05], bupropion treatment [F(1,56) = 3.12,
P N 0.05], TNF-α × α-tocopherol treatment interaction [F(1,56) =
1.85, P N 0.05], TNF-α × bupropion treatment interaction [F(1,56) =
0.11, P N 0.05], α-tocopherol × bupropion treatment interaction
[F(1,56) =0.07, P N 0.05], TNF-α × α-tocopherol × bupropion treat-
ment interaction [F(1,56) = 1.03, P N 0.05]).
3.1.3. Effects of the combined administration of α-tocopherol and
MK-801 or 7-nitroindazole in TNF-α-treated mice
Fig. 3 shows that acute administration of a subeffective dose of
α-tocopherol in combination with subeffective doses of MK-801
(panel A) or 7-nitroindazole (panel C) reduced the immobility time
in the TST in control mice (not treated with TNF-α), while the adminis-
tration of these drugs alone did not change this parameter. The animals
that received TNF-α had an increased immobility time in the TST.
However, when mice that received TNF-α were pretreated with
α-tocopherol, MK-801, 7-nitroindazole or the combined treatment
with α-tocopherol and MK-801, no depressive-like behavior was
observed. Interestingly, combined treatment with α-tocopherol and
7-nitroindazole (panel C) elicited a synergistic antidepressant-like
effect in mice treated with TNF-α, since statistically lower immobility
time values were obtained as compared to the values obtained in the
groups of mice that received α-tocopherol or 7-nitroindazole alone
(MK-801: TNF-α treatment [F(1,56) = 12.73, P b 0.01], α-tocopherol
treatment [F(1,56) = 45.69, P b 0.01], MK-801 treatment [F(1,56) =
33.89, P b 0.01], TNF-α × α-tocopherol treatment interaction
[F(1,56) = 3.35, P N 0.05], TNF-α × MK-801 treatment interaction
[F(1,56) = 0.25, P N 0.05], α-tocopherol × MK-801 treatment interac-
tion [F(1,56) = 0.07, P N 0.05], TNF-α × α-tocopherol × MK-801
treatment interaction [F(1,56) = 41.91, P b 0.01]; 7-nitroindale:
TNF-α treatment [F(1,54) = 4.74, P b 0.05], α-tocopherol treatment
[F(1,54) = 30.06, P b 0.01], 7-nitroindazole treatment [F(1,54) =
62.95, P b 0.01], TNF-α × α-tocopherol treatment interaction
[F(1,54) = 0.23, P N 0.05], TNF-α × 7-nitroindazole treatment interac-
tion [F(1,54) = 2.58, P N 0.05], α-tocopherol × 7-nitroindazole treat-
ment interaction [F(1,54) = 9.34, P b 0.01], TNF-α ×α-tocopherol ×
7-nitroindazole treatment interaction [F(1,54) = 10.12, P b 0.01]).
A B
C D
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Fig. 2. Effect of treatmentwith a subeffective dose ofα-tocopherol (T) (10 mg/kg, p.o.) and/or subeffective dose ofﬂuoxetine (FLU) (5 mg/kg, p.o.), imipramine (0.1 mg/kg, p.o.) or bupropion
(BUP) (1 mg/kg, p.o.) associatedwith administration of TFN-α (0.001 fg/site; i.c.v.) or vehicle on the immobility time in the TST (panels A, C, E) and on number of crossings in the open-ﬁeld
test (panels B, D, F). Bars represent means + SEM (n = 7–8). *P b 0.05 compared with the control group (vehicle). **P b 0.01 compared with control (vehicle). ##P b 0.01 compared with
group treated with TNF-α. $$P b 0.01 compared with group T10/TNF-α and with the group antidepressant/TNF-α. (Three-way ANOVA followed by Duncan's post hoc test).
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open-ﬁeld test (Fig. 3B, D) (MK-801: TNF-α treatment [F(1,56) =
0.08, P N 0.05], α-tocopherol treatment [F(1,56) = 1.37, P N 0.05],
MK-801 treatment [F(1,56) = 0.82, P N 0.05], TNF-α × α-tocopherol
treatment interaction [F(1,56) = 0.50, P N 0.05], TNF-α × MK-801
treatment interaction [F(1,56) = 1.84, P N 0.05], α-tocopherol ×
MK-801 treatment interaction [F(1,56) = 0.02, P N 0.05], TNF-α ×
α-tocopherol × MK-801 treatment interaction [F(1,56) = 0.12, P N
0.05]; 7-nitroindale: TNF-α treatment [F(1,55) = 0.0005, P N 0.05],
α-tocopherol treatment [F(1,55) = 0.02, P N 0.05], 7-nitroindazole
treatment [F(1,55) = 6.80, P b 0.05], TNF-α × α-tocopherol treatment
interaction [F(1,55) = 0.52, P N 0.05], TNF-α × 7-nitroindazole
treatment interaction [F(1,55) = 0.09, P N 0.05], α-tocopherol ×
7-nitroindazole treatment interaction [F(1,55) = 0.002, P N 0.05],
TNF-α × α-tocopherol ×7-nitroindazole treatment interaction
[F(1,55) =0.04, P N 0.05]).
3.2. Bax and Bcl2 immunocontent and GSK-3β phosphorylation
Fig. 4 shows a representative western blot of the hippocampal
immunocontent of Bax (panel A) and Bcl2 (panel B) of mice injected
with TNF-α and pretreated with α-tocopherol (10 and 30 mg/kg) or
bupropion (10 mg/kg). Densitometric analysis revealed no changes inthe content of Bax (panel A) and Bcl2 (panel B) in hippocampus of
mice, independent on the treatment condition (Bax: TNF-α treatment
[F(1,24) = 0.2278, P N 0.05], treatment [F(3,24) = 0.0225, P N 0.05],
TNF-α ×treatment interaction [F(3,24) = 0.3318, P N 0.05]; Bcl2: TNF-α
treatment [F(1,24) = 1.4328, P N 0.05], treatment [F(3,24) = 0.2001,
P N0.05], TNF-α × treatment interaction [F(3,24) = 0.1221, P N 0.05]).
Similarly, no alteration in GSK-3β phosphorylation (Ser9) in the hippo-
campus was observed in any experimental group (panel C) (TNF-α
treatment [F(1,24) = 0.1178, P N 0.05], treatment [F(3,24) = 0.2869,
P N 0.05], TNF-α × treatment interaction [F(3,24) = 0.3998, P N 0.05]).
4. Discussion
This study demonstrated that: a) TNF-α administered acutely by
i.c.v. route produces a depressive-like behavior in the TST; b) different
doses of α-tocopherol, administered systemically (p.o.) and acutely
were able to prevent the behavioral effects induced by TNF-α; c)
the combined acute administration of subeffective doses of
α-tocopherol with subeffective doses of antidepressants (ﬂuoxetine,
imipramine and bupropion), NMDA receptor antagonist (MK-801)
and nNOS inhibitor (7-nitroindazole) caused a reduction of immobil-
ity time in the TST either in mice treated with TNF-α or in mice treat-
ed with vehicle; and d) treatment with TNF-α and/or α-tocopherol
A B
C D
Fig. 3. Effect of treatmentwith subeffective dose ofα-tocopherol (T) (10 mg/kg, p.o.) and/or subeffective dose ofMK-801 (0.001 mg/kg, p.o.) or 7-nitroindazole (7-Nitro) (25 mg/kg, p.o.)
associatedwith administration of TFN-α (0.001 fg/site; i.c.v.) or vehicle on the immobility time in the TST (panels A, C) and onnumber of crossings in the open-ﬁeld test (panels B, D). Bars
representmeans + SEM (n = 7–8). **P b 0.01 comparedwith control (vehicle). ##P b 0.01 comparedwith group treatedwith TNF-α. $$P b 0.01 comparedwith group T10/TNF-α and
with the group antidepressants/TNF-α. (Three-way ANOVA followed by Duncan's post hoc test).
C
A B
Fig. 4. Effect of treatment withα-tocopherol (T; 10–30 mg/kg, p.o.) or bupropion (BUP) (10 mg/kg, p.o.) associated with administration of TFN-α (0.001 fg/site; i.c.v.) or vehicle on the
immunocontent of Bax (panel A), Bcl2 (panel B) and phosphorylation (Ser9) (panel C) of glycogen synthase kinase-3β (GSK-3β) in the hippocampus of mice. Immunocontent of Bax and
Bcl2 and phosphorylation of GSK-3βwere assessed by western blotting and revelation was performed by chemiluminescence. The densitometry of bands was determined using the Scion
Image software®. A representative image and quantitative analysis normalized to the total-GSK-3β (t-GSK) (upper bands, p-GSK-3β; lower bands, t-GSK-3β) andβ-actin (upper bands, Bax
or Bcl2; lower bands, β-actin) bands are shown. The results are expressed as the percentage of vehicle control levels and represent the mean + SEM (n = 4) (two-way ANOVA).
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phosphorylation.
TNF-α is a protein that can be produced by several cell types, includ-
ing monocytes, lymphocytes, macrophages, neurons and glial cells in
response to infection, injury, inﬂammation or other environmental
changes (Baud and Karin, 2001; Tchelingerian et al., 1994). This cyto-
kine exerts its actions by interacting with speciﬁc receptors for tumor
necrosis factor types 1 and 2, leading to activation of signaling cascades
that regulate pro- and antiapoptotic pathways, cell proliferation and in-
ﬂammation (Baud and Karin, 2001). The ﬁrst demonstrations that de-
pressed patients had increased TNF-α levels, were shown by
Lanquillon et al. (2000), Mikova et al. (2001) and Kagaya et al. (2001),
and this association has been conﬁrmed by other studies and meta-
analysis (Dowlati et al., 2010; O'Brien et al., 2007). Furthermore, psy-
chological stress, which is also correlated with depression, also causes
an increase on inﬂammatory cytokines, including TNF-α (Glaser and
Kiecolt-Glaser, 2005; Lalive et al., 2002) and mice with TNF-α receptor
deﬁciency had alteration in anxiety-like behavioral and neuroendocrine
stress responses (Gimsa et al., 2012).
Herein we observed that administration of TNF-α induced a
depressive-like behavior in the mouse TST, conﬁrming a previous
study (Kaster et al., 2012), which showed that the administration of
the same dose of TNF-α increased the immobility time of mice exposed
to TST. In rats, chronic administration of recombinant rat TNF-α (via
i.c.v.) also elicits depressive-like behavior (Reynolds et al., 2004). Fur-
thermore, Kaster et al. (2012) demonstrated that the use of inhibitor
of TNF-α synthesis prevented the increase in immobility time induced
by this cytokine in the forced swimming test (FST), reinforcing the
idea that the elevated levels of TNF-α in mice brain are related to the
depressive-like behavior in these animals. Corroborating these data,
studies reported that TNF-α receptor knockout mice exhibited a
decrease in immobility time in the TST and FST (Kaster et al., 2012;
Simen et al., 2006) and that mice lacking the gene for TNF-α demon-
strated a shorter duration of immobility in the FST when compared to
control animals (Yamada et al., 2000).
In the present study, the acute administration of α-tocopherol
30 min before the injection of TNF-α was able to prevent the increase
of immobility time caused by TNF-α. In line with this result,
α-tocopherol attenuated the sickness behavior induced by lipopolysac-
charides (Berg et al., 2004; Godbout et al., 2005) as well as decreased
the expression of nuclear factor-κB (NFκB), IL-6, IL-1β and TNF-α in
the brain of mice that had received lipopolysaccharide (Godbout et al.,
2005). In addition, two preclinical studies using predictive tests for eval-
uation of antidepressant activity (TST and FST), showed that
α-tocopherol reduces the duration of immobility time in mice (Lobato
et al., 2010) and rats (Parveen, 2011). It is worth mentioning that, in
our study, no signiﬁcant change in the number of crossings in the
open-ﬁeld test after administration of TNF-α or α-tocopherol was
shown, indicating that the behavioral effects of the cytokine and
α-tocopherol observed in the present study are not due to any change
in the locomotor activity. Indeed, our results are consistent with the fact
that several classes of antidepressants such as tricyclics (amitriptyline,
desipramine, imipramine), MAO inhibitors (clorgyline, moclobemide,
nialamide, pargyline, toloxatone) and atypical antidepressants
(bupropion, citalopram, indalpine, mianserin, nomifensine, viloxazine)
decrease the duration of immobility time in the TST (Steru et al., 1987).
Even these drugs taking several weeks to obtain an improvement in
the clinical setting, they show antidepressant effect in the TST when
administered acutely.
Another interesting result found in the presentwork is that the asso-
ciated acute administration of subeffective doses of antidepressants
(ﬂuoxetine, imipramine and bupropion) with a subeffective dose of
α-tocopherol elicited an antidepressant-like behavior in mice that
received vehicle. This result is in agreementwith the reported synergis-
tic antidepressant-like effect in the FST elicited by the combined admin-
istration of α-tocopherol and ﬂuoxetine (Lobato et al., 2010).Furthermore, subeffective doses of α-tocopherol and antidepressants
alone or in combination prevented the depressive-like behavior in-
duced by TNF-α and that the combined treatment with imipramine or
bupropion and α-tocopherol resulted in a synergistic antidepressant-
like effect in animals receiving TNF-α, suggesting that the
antidepressant-like effect of α-tocopherol involves, at least in part,
the modulation of serotonergic, dopaminergic and noradrenergic sys-
tems. It is well established the role of monoamine neurotransmitters
(serotonin, noradrenaline, and dopamine) in depression (Andrews et
al., 2011; Elhwuegi, 2004), and the involvement ofmonoaminergic neu-
rotransmission in antidepressant-like response in animal models of de-
pression (Elhwuegi, 2004; Yamada et al., 2004). Additionally, vitamin E
was reported to interfere with monoamine levels in the brain of rats
(Adachi et al., 1999; Castano et al., 1992). Castano et al. (1992) showed
that 15 days of vitamin E-deﬁcient diet led to a decrease in serotonin
levels and an increase in dopamine levels in the rat brains. In the
study performed by Adachi et al. (1999), vitamin E-deﬁcient diet for
24 weeks decreased the levels of serotonin, dopamine and the activity
of tryptophan hydroxylase enzyme (involved in the formation of sero-
tonin) in the brain stem of rats. Likewise, similar to the ﬁnding of our
study, other vitamins that also have antidepressant-like activity in ani-
mal models, such as ascorbic acid and folic acid, also seem to interact
with monoaminergic systems to produce their behavioral effects
(Binfaré et al., 2009; Brocardo et al., 2008).
In addition, some studies have shown that antidepressants that alter
the monoaminergic system (e.g., ﬂuoxetine, bupropion, citalopram)
have antioxidant and anti-inﬂammatory properties (Abdel-Salam
et al., 2004; Behr et al., 2012; Sacre et al., 2010; Zaﬁr and Banu, 2007;
Zaﬁr et al., 2009). Therefore, we suggest that the antidepressant-like ef-
fect of α-tocopherol might be due, at least in part, from its antioxidant
and/or anti-inﬂammatory actions. Studies have demonstrated that die-
tary supplementation of antioxidants with α-tocopherol (alone or in
combination with other antioxidants), prevented oxidative stress in
the rat brain (dos Santos et al., 2011; Thakurta et al., 2012) and that
α-tocopherol dietary supplementation prevented oxidative stress and
neuroglial over-activation, acting as an antioxidant and reducing
neuroinﬂammation (Betti et al., 2011). In humans, supplementation
with vitamin E also decreases lipid peroxidation, increases antioxidant
enzyme activity (Shinde et al., 2011; Zal et al., 2011) and decreases
inﬂammation (Devaraj et al., 2007; Wu et al., 2007).
Noteworthy, an antidepressant-like effect in animal models has
been reported to be elicited by the administration of some nutrients,
phytochemicals, herbal or substances with antioxidant and/or
anti-inﬂammatory properties, such as omega-3 fatty acids (Venna et
al., 2009), curcumin (Kulkarni et al., 2008), green tea polyphenols
(Zhu et al., 2012), Ginkgo biloba extract (Rojas et al., 2011), coenzyme
Q10 (Maes et al., 2009), N-acetylcysteine (Ferreira et al., 2008), and
ascorbic acid (Binfaré et al., 2009; Moretti et al., 2012).
The glutamatergic system and the L-arginine–NO pathway have
also been reported to be associated with psychiatric disorders (Dhir
and Kulkarni, 2011; Skolnick, 1999; Zarate et al., 2010). Several
preclinical studies have reported that NMDA receptor antagonists
exert antidepressant-like effects in animal models of depression
(Dhir and Kulkarni, 2008; Li et al., 2011) and that compounds with
antidepressant properties have their effect potentiated by the reduc-
tion of NO levels. In addition, an increased level of NO prevents the
antidepressant-like activity of these compounds (Bettio et al., 2012;
Brocardo et al., 2008; Moretti et al., 2011). Human studies have also
shown that NMDA receptor antagonists are capable of decreasing de-
pressive symptoms (DiazGranados et al., 2010; Zarate et al., 2006),
and that depressed patients who attempted suicide had higher plas-
ma levels of NO than the control ones (Kim et al., 2006).
Furthermore, excessive amounts of nitric oxidemay reactwith super-
oxide anions, which generate peroxynitrite anions and peroxynitrous
acid, causing tissue toxicity and stimulating nitrosative stress, factors
that are associated with depressive symptoms (Maes et al., 2011).
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depression through multiple mechanisms, e.g. damage to DNA, mito-
chondria, proteins and membrane polyunsaturated fatty acid omega-3
contents; damage to intracellular signaling molecules involved in the
pathophysiology of depression; superinduction of the enzyme that con-
verts tryptophan to the kynurenine pathway (Leonard andMaes, 2012).
In the present study, the acute administration of subeffective
doses of α-tocopherol, NMDA receptor antagonist or nNOS inhibitor
alone or in combination abolished the depressive-like behavior
induced by TNF-α. Moreover, the combination of α-tocopherol with
7-nitroindazole resulted in a synergistic antidepressant-like effect in
animals treated with TNF-α, suggesting that a modulation of NO pro-
duction may account for the beneﬁcial effects of α-tocopherol in this
experimental protocol.
It is worth mentioning that some studies also demonstrate that
α-tocopherol may inﬂuence the glutamatergic system, since it was
reported to prevent the glutamate-induced increase in intracellular
calcium concentration and production of reactive oxygen species as
well as DNA and mitochondrial damage in HT4 neuronal cells
(Tirosh et al., 2000). In addition,α-tocopherol was effective in lowering
intracellular calcium in rat brain synaptosomes treated with glutamate
(Avrova et al., 1999). Regarding L-arginine–NOpathway, although some
studies have linked the beneﬁcial effects of α-tocopherol with higher
activity of NOS and consequent increase in NO production (Heller
et al., 2004; Li et al., 2001; Tronchini et al., 2010), these studies investi-
gated only peripheral actions of vitamin E, not evaluating issues related
to the CNS and nNOS, speciﬁcally. However, taking into account that
α-tocopherol is an antioxidant, it can prevent/avoid some of the dam-
age caused by oxidative and nitrosative stress (Leonard and Maes,
2012). Therefore, adequate levels of vitamin E would be interesting
for patients with depression. Corroborating this information, studies
have shown that depressive patients have lower levels of vitamin E
(Maes et al., 2000; Owen et al., 2005); that decrease in the dietary
intake of vitamin E was associated with depression (German et al.,
2012); and that nurses with high job stress hadmore severe depressive
symptoms and lower plasma concentrations of α-tocopherol (Tsuboi
et al., 2006).
After obtaining the results discussed so far, we evaluated if the ani-
mal model of depressive-like behavior induced by TNF-α would lead
to any changes in proteins involved in apoptotic pathways, as well as
the effect of α-tocopherol in this experimental paradigm. Literature
data have demonstrated that, in vitro, IFN-γ (an inﬂammatory cyto-
kine) was able to increase the levels of Bax and decrease levels of Bcl2
(Ning et al., 2010) and that TNF-α was able to increase the nuclear
expression of GSK-3β (Park et al., 2011). In addition to the
well-known effect of inﬂammation in apoptotic pathways, a recent
review correlated several animal models of depressive-like behavior
(chronic mild stress, learned helplessness) with increased inﬂamma-
tion and alteration in apoptotic pathways, including decreased Bcl2 ex-
pression (Kubera et al., 2011). In this work, no signiﬁcant alterationwas
observed in the levels of Bax and Bcl2 and phosphorylation of GSK-3β
(Ser9) in the hippocampus of mice that received TNF-α. However, the
Bcl2 results should be considered with caution, because although not
statistically signiﬁcant, a slight decrease on Bcl2 immunocontent in an-
imals treated with bupropion or α-tocopherol associated with TNF-α
was shown. We do not rule out the possibility that it could attain a
statistical signiﬁcance with an increase in the number of samples
analyzed.
A recent study performed by our group showed that acute re-
straint stress elicited depressive-like behavior and increased oxida-
tive stress in the brain of mice (Moretti et al., 2013), alterations that
could be result in a neutrophil-mediated inﬂammation (Juurlink and
Paterson, 1998). However, somewhat similar to our study, Moretti
et al. (2013) observed no effect of stress on GSK-3β phosphorylation
or on BAX levels, while only an increased hippocampal level of Bcl2
was reported.Studies also demonstrated that chronic treatment with antidepres-
sants (such as ﬂuoxetine, citalopram, desipramine, imipramine) mod-
iﬁes the Bax and Bcl2 levels (Bachis et al., 2008; Huang et al., 2007;
Murray and Hutson, 2007) and that acute treatment with ﬂuoxetine or
imipramine altered GSK-3 phosphorylation (Li et al., 2004; Roh et al.,
2005; Su et al., 2012). However, citalopram, imipramine and amitripty-
line, when given acutely, failed to alter the levels of Bcl2 (Murray and
Hutson, 2007). Here, administration of α-tocopherol or bupropion in
an active dose did not signiﬁcantly affect the levels of Bax and Bcl2 or
phosphorylation of GSK-3β. However, studies in the literature show
that vitamin E can alter the levels of Bax and/or Bcl2 or GSK-3 phosphor-
ylation in different cell types and experimental protocols (Magalhães et
al., 2007; Marsh et al., 2005). Studies involving the CNS show that: a) in
rat cortical neurons, the administration of α-tocopherol prevented cell
death induced by hydrogen peroxide, besides increasing Bcl2 expression
via mitogen-activated protein kinase (MAPK) and phosphatidylinositol
3-kinase (PI3K) (Numakawa et al., 2006); b) in rats, treatment with
α-tocopherol prevented the increase of the Bax:Bcl2 ratio in the hippo-
campus and caudate nucleus induced by haloperidol — a medication
used for treating psychotic disorders (Post et al., 2002); and c)
α-tocopherol was also able to inhibit dephosphorylation of GSK-3β
in oligodendrocytes treated with 7-ketocholesterol (which induces
apoptosis) (Ragot et al., 2011).
One drawback of the present study is that the evaluation of Bcl2
and BAX was performed in a time period that was likely not enough
to cause alterations in the expression of proteins involved in the
control of apoptosis. Also, particularly regarding Bcl2 immunocontent,
the number of samples used may not have been enough to detect a
signiﬁcant statistical difference. Therefore, the possibility that TNF-α
and/or α-tocopherol may modulate the apoptotic pathway mediated
by these proteins cannot be ruled out. We believe that the differences
between the results obtained in our study and those available in the
literature may be also due to the duration of α-tocopherol treatment.
5. Conclusions
The administration of TNF-α elicited a depressive-like behavior
in mice exposed to TST, which was prevented by pre-administration
of α-tocopherol. Moreover, a synergistic antidepressant-like effect of
α-tocopherol with antidepressants was shown, even in the presence
of an inﬂammatory insult, suggesting that this vitaminmay be interest-
ing to optimize conventional pharmacotherapy for depression, includ-
ing depressive states associated with inﬂammatory conditions. Hence,
the present study suggests that α-tocopherol might improve the effec-
tiveness of antidepressant compounds used in the clinical and that this
vitamin may be useful in treating patients with intolerable side effects
or who are resistant to therapy with a single antidepressant. However,
additional preclinical studies and clinical trials are needed to better
elucidate this effect.
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